-The Hindu India’s IPR regime, never in the background, has come under sharp focus recently for a variety of reasons. It is ten years since India amended the Indian Patents Act, 1970 to bring its laws in line with the agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS). The most important of those amendments related to the introduction of product patents for 20 years, including for pharmaceutical products. Significant safeguards were...

-Hindustan Times The government is set to re-launch its pharmacy chain, Jan Aushadhi, to sell generic drugs ranging from anti-biotics, anti-cardiac, anti-infective and gastro intestinal drugs at prices at least half of branded drugs. The project would be launched in six states on a pilot basis from June 21, where 5,000 stores would be opened across the country in a phased manner. The scheme failed in 2008 due to poor supply-chain management. “Now, we...

-The Indian Express Government has been speaking in two tongues on intellectual property. Last week, Prime Minister Narendra Modi expressed his desire to see India adhere to “global” IP standards. The United States Trade Representative (USTR) was quick to latch on to this, noting in its latest Special 301 report: “The United States also welcomes April 2015 statements made by Prime Minister Modi recommending that India align its patent laws with international...

-Economic and Political Weekly Ten years on, the progressive provisions of the amended Indian Patents Act are being watered down. Ten years have passed since the Indian Patents Act, 1970 was amended in 2005 to bring the country’s laws in line with the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS). The most important of the 2005 amendments was the introduction of product patents for 20 years, including for pharmaceutical products,...

-The Hindu It was resolved that all IMA members shall write drugs with chemical or generic name in capital letters A resolution was passed at the recent working committee meeting of the Indian Medical Association (IMA) that is likely to have the direct benefit of making drugs more accessible and affordable. It was resolved that all IMA members “shall write drugs with chemical or generic name in capital letters, and the name of...